Biotechnology company Revance Therapeutics Inc (Nasdaq:RVNC) revealed on Tuesday that the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under US FDA review for the treatment of glabellar lines in 2021.
Revance said that DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.
In conjunction, the company provided its response to the Form 483 and is confident in the quality of its DaxibotulinumtoxinA for Injection BLA submission and continues to anticipate FDA approval in 2021. A Form 483 does not constitute a final agency determination.
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant